CureVac Swiss initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic

CureVac

19 April 2021 - Review process started with submission of first CVnCoV data package.

CureVac Swiss today announced initiation of a rolling submission for CVnCoV, the company’s mRNA based COVID-19 vaccine candidate, for the use in Switzerland. 

The application for authorisation was submitted to Swissmedic, the country’s authority responsible for the authorisation and supervision of therapeutic products including vaccines.

Read CureVac press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Vaccine , Dossier , Switzerland , COVID-19